| |
Article Title |
Author(s) |
Pages |
|
|
|
Editorial Board / Aims & Scope
|
|
iii
|
|
|
|
Evaluation of prognostic factors in AML
Over the past decade and a half, a virtual explosion in the identification of genes and mutations has enhanced our understanding of the biology of acute myeloid leukemia (AML) as well as offered poten...
|
Jacob M. Rowe
|
485-488
|
|
|
|
Genomic profiling of B-progenitor acute lymphoblastic leukemia
Childhood acute lymphoblastic leukemia (ALL) is comprised of multiple subtypes defined by recurring chromosomal alterations that are important events in leukemogenesis and are widely used in diagnosis...
|
Charles G. Mullighan
|
489-503
|
|
|
|
Flow cytometry in the post fluorescence era
While flow cytometry once enabled researchers to examine 10–-15 cell surface parameters, new mass flow cytometry technology enables interrogation of up to 45 parameters on a single cell. This new tech...
|
Garry P. Nolan
|
505-508
|
|
|
|
Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?
Minimal residual disease (MRD) monitoring, particularly via multiparameter flow (MPF) cytometry assessed after chemotherapy, has been very useful in the prognostic and therapeutic approach for childre...
|
Richard M. Stone
|
509-514
|
|
|
|
What is the optimal induction strategy for older patients?
Prognoses of older patients (age ≥60 years) vary greatly following use of standard therapy, such as 3 + 7: 3 days of daunorubicin or idarubicin + 7 days of cytarabine (ara-C). Although most older pati...
|
Elihu Estey
|
515-522
|
|
|
|
Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants?
Do patients with therapy-related acute myeloid leukemia (t-AML) have a poor prognosis independent of other predictive variables such as cytogenetics or molecular determinants? Limited data exist to an...
|
Eric J. Feldman
|
523-526
|
|
|
|
Is a nadir bone marrow required and, if so, what to do with residual disease?
Current National Comprehensive Cancer Network guidelines for acute myeloid leukemia (AML) treatment state that bone marrow biopsies should be completed 7–10 days after completion of chemotherapy. Trea...
|
Selina M. Luger
|
527-532
|
|
|
|
Targeted immunotherapy for acute myeloid leukemia
Allogeneic hematopoietic stem cell transplantation (HSCT) demonstrated convincingly the potential of allogeneic T cells in causing sustained remissions in high-risk hematologic malignancies. However t...
|
Sumithira Vasu,
Michael A. Caligiuri
|
533-540
|
|
|
|
The role of hematopoietic cell transplantation as therapy for myelodysplasia
A recent American Society of Blood and Marrow Transplantation (ASBMT) position paper concluded that allogeneic hematopoietic cell transplantation (HCT) is recommended for patients with myelodysplastic...
|
Frederick R. Appelbaum
|
541-547
|
|
|
|
Transplants for leukemia in relapse: When is the best time?
Transplantation of hematopoietic cells to treat acute leukemia can offer disease control and extended survival for a sizeable fraction of patients, but because alternative approaches may also be effec...
|
Daniel Weisdorf
|
549-552
|
|
|
|
What is the potential for thrombopoietic agents in acute leukemia?
In the 16 years since thrombopoietin was identified and cloned, much has been learned about its biochemistry, how it is regulated, and its involvement in a wide range of functions in a variety of cell...
|
David J. Kuter
|
553-558
|
|
|
|
Research and discovery of the first human cancer virus, HTLV-1
Human T-cell lymphoma virus (HTLV)-1 was the first human retrovirus to be discovered. It has been recognized as the cause of adult T-cell leukemia (ATL). In addition to giving a historical perspective...
|
Robert C. Gallo
|
559-565
|
|
|
|
Index
|
|
I
|
|
